Select Publications

Geyer CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res Treat 2003;Abstract 23.

Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 2001;285(Suppl 16):41-6. Abstract

Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002;3(3):137-44. Abstract

Leyland-Jones B, Smith I. Role of Herceptin in primary breast cancer: views from North America and Europe. Oncology 2001;61(Suppl 2):83-91. Abstract

Nabholtz JM et al. HER2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin Breast Cancer 2002;3(Suppl 2):75-9. Abstract

Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001;281(Suppl 3):1-12. Abstract

Pegram MD, O'Callaghan C. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clin Breast Cancer 2001;2(Suppl 1):15-9. Abstract

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;281(Suppl 3):13-9. Abstract

Smith I. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab. Ann Oncol 2001;12(Suppl 1):75-9. Abstract

Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 2001;28(1 Suppl 3):20-7. Abstract

Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003;30(5 Suppl 16):54-64. Abstract

Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63(Suppl 1):57-63. Abstract